Robert Scully - Zoetis Independent Director

ZTS -- USA Stock  

USD 123.24  0.82  0.67%

  Director
Mr. Robert W. Scully is Independent Director of the Company. Mr. Scully has nearly 35 years of experience in the financial services industry. He served as a member of the Office of the Chairman of Morgan Stanley from 2007 until his retirement in January 2009, where he had previously been CoPresident of the firm, Chairman of global capital markets and Vice Chairman of investment banking. Prior to joining Morgan Stanley in 1996, he served as a Managing Director at Lehman Brothers and at Salomon Brothers Inc. He currently serves on the boards of KKR Co. Inc., a private equity and asset management firm Chubb Limited, a global property and casualty company and UBS Group AG, a global financial services company. Previously, he served as a director of Bank of America Corporationrationration, GMAC Financial Services and MSCI Inc., and as a Public Governor of FINRA, Inc., the Financial Industry Regulatory Authority. Mr. Scully holds a bachelors degree from Princeton University and an MBA from Harvard Business School, where he previously served on its Board of Deans Advisors
Age: 68  Director Since 2013      
973-822-7000  http://www.zoetis.com
Scully?s global management experience, financial acumen, M&A expertise and investor insights, along with his public company board experience, make him a valuable member of our Board.

Robert Scully Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

David BullockOrigin Agritech Limited
2015
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Bharat DoshiDr Reddys Laboratories Ltd
2016
J MoreauDr Reddys Laboratories Ltd
2007
Laurie BrlasPerrigo Company plc
2016
Gary CohenPerrigo Company plc
2009
Adriana KaraboutisPerrigo Company plc
2017
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Rolf ClassonPerrigo Company plc
2017
David AltshulerVertex Pharmaceuticals Incorpor
2015
Larry CordellOrigin Agritech Limited
2012
Shlomo YanaiPerrigo Company plc
N/A
Charles BakerRegeneron Pharmaceuticals
N/A
Jeffrey SmithPerrigo Company plc
2017
Bruce CarterDr Reddys Laboratories Ltd
2008
Huda ZoghbiRegeneron Pharmaceuticals
2016
James KangOrigin Agritech Limited
2010
Geoffery MerszeiOrigin Agritech Limited
2016
Geoffrey ParkerPerrigo Company plc
2016
Kalpana MorpariaDr Reddys Laboratories Ltd
2007

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 300 shares of
few hours ago
Traded for 35.11
Sold over 200 shares of
few hours ago
Traded for 47.76
Purchased over 100 shares of
few hours ago
Traded for 4.78
See also Your Current Watchlist. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Search macroaxis.com